Frontiers in genetics · 2026
Clinical and genomic characterization of corpus callosum abnormalities (CCA) in 107 Tunisian patients using a stepwise diagnostic approach.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khadija Bochra, Abdallah Hamza Hadj, Slimani Wafa, Bennour Ayda, Dimassi Sarra, Soyah Najla, Benzarti Amira, Rjiba Khouloud, Dahleb Wafa, Kammoun Molka, Hannechi Hanen, Khelifa Hela Ben, Khouja Neziha Gouider, Boughamoura Lamia, Kraoua Ichrak, Triki Chahnaz, Tej Amel, Mathlouthi Jihen, Guith Aida, Abroug Saoussen, Kebaili Raoudha, Bouaziz Mohamed Ali, Soua Habib, Sboui Essia, Hadded Samir, Ziadi Randa, Monastiri Kamel, Ben Hamida Hayet, Ghanmi Monji, Hassayoun Sayda, Sfar Mohamed Tahar, Saad Ali, Depienne Christel, Mougou-Zerelli Soumaya
Аннотация
BACKGROUND: Corpus callosum abnormalities (CCA) represent a heterogeneous group of neurodevelopmental disorders resulting from disturbances in midline patterning, neuronal migration, and axonal guidance. Their genetic architecture includes chromosomal abnormalities, pathogenic copy-number variations (CNVs), and single-gene disorders; however, genotype-phenotype correlations remain incompletely defined, particularly in underrepresented populations.
METHODS: We investigated the clinical and genomic characteristics of 107 Tunisian patients with radiologically confirmed CCA recruited over a 15-year period. A sequential genomic strategy was applied, including conventional karyotyping in all patients, fluorescence in situ hybridization (FISH) and multiplex ligation-dependent probe amplification (MLPA) when clinically indicated, chromosomal microarray analysis (array-CGH) in 54 selected patients, and whole-exome sequencing (WES) in six unresolved cases. CNVs were interpreted according to ACMG/ClinGen recommendations, and sequence variants were classified according to ACMG/AMP criteria.
RESULTS: Most patients presented syndromic forms of CCA (95.3%) associated with additional cerebral and/or extracerebral manifestations. Clinically relevant genomic abnormalities supporting a molecular diagnosis were identified in 11/107 patients (10.3%). Conventional karyotyping identified chromosomal abnormalities in three patients (2.8%), while array-CGH detected pathogenic or likely pathogenic CNVs in ten of 54 tested patients (18.5%). These CNVs involved genomic regions previously implicated in neurodevelopmental disorders and CCA, including 14q12, 4p16.3-p16.1, 1q43-q44, 1p32.3p31.3 -p32, 5p14.3, 5q35, 16q23.1-q24.3, and 18pterp11.1. WES identified rare variants in WLS, ERCC8, and VPS39, while a MID1 variant was classified as likely benign. No sequence variant met ACMG/AMP criteria for pathogenicity, and none was considered diagnostic.
CONCLUSION: This study provides a comprehensive characterization of CCA in a Tunisian referral cohort and highlights the major contribution of pathogenic genomic imbalances to the molecular diagnosis of these disorders. The findings emphasize the complementary role of cytogenetic and sequencing approaches while illustrating the challenges of interpreting rare sequence variants in patients with complex neurodevelopmental phenotypes. Larger cohorts with systzbematic genomic testing, segregation analyses, and functional validation will be required to further refine genotype-phenotype correlations in CCA.
METHODS: We investigated the clinical and genomic characteristics of 107 Tunisian patients with radiologically confirmed CCA recruited over a 15-year period. A sequential genomic strategy was applied, including conventional karyotyping in all patients, fluorescence in situ hybridization (FISH) and multiplex ligation-dependent probe amplification (MLPA) when clinically indicated, chromosomal microarray analysis (array-CGH) in 54 selected patients, and whole-exome sequencing (WES) in six unresolved cases. CNVs were interpreted according to ACMG/ClinGen recommendations, and sequence variants were classified according to ACMG/AMP criteria.
RESULTS: Most patients presented syndromic forms of CCA (95.3%) associated with additional cerebral and/or extracerebral manifestations. Clinically relevant genomic abnormalities supporting a molecular diagnosis were identified in 11/107 patients (10.3%). Conventional karyotyping identified chromosomal abnormalities in three patients (2.8%), while array-CGH detected pathogenic or likely pathogenic CNVs in ten of 54 tested patients (18.5%). These CNVs involved genomic regions previously implicated in neurodevelopmental disorders and CCA, including 14q12, 4p16.3-p16.1, 1q43-q44, 1p32.3p31.3 -p32, 5p14.3, 5q35, 16q23.1-q24.3, and 18pterp11.1. WES identified rare variants in WLS, ERCC8, and VPS39, while a MID1 variant was classified as likely benign. No sequence variant met ACMG/AMP criteria for pathogenicity, and none was considered diagnostic.
CONCLUSION: This study provides a comprehensive characterization of CCA in a Tunisian referral cohort and highlights the major contribution of pathogenic genomic imbalances to the molecular diagnosis of these disorders. The findings emphasize the complementary role of cytogenetic and sequencing approaches while illustrating the challenges of interpreting rare sequence variants in patients with complex neurodevelopmental phenotypes. Larger cohorts with systzbematic genomic testing, segregation analyses, and functional validation will be required to further refine genotype-phenotype correlations in CCA.